0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > TNFR2

TNFR2

Brief Information

Name:Tumor necrosis factor receptor superfamily member 1B
Target Synonym:TNFR-II,TNFR80,TNF-RII,p80 TNF-alpha receptor,p75,Tumor necrosis factor receptor 2,Etanercept,TBP-2,Tumor necrosis factor receptor type II,TBPII,CD120b,TNF-R-II,CD120b Antigen,Tumor Necrosis Factor Beta Receptor,Soluble TNFR1B Variant 1,Tumor Necrosis Factor Binding Protein 2,TNFBR,TNF Receptor Superfamily Member 1B,TNFR2,P75 TNF Receptor,P75TNFR,TNFR1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,TNF-R75,TNF-R2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
TNFRⅡ fusion protein(biosimilar) Fusion/Recombination protein Immunological disease Rheumatoid Arthritis,Psoriasis,Ankylosing Spondylitis NDA/BLA Global  (except China)

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

TN2-H82F3-ELISA
 TNFR2 ELISA

Immobilized Human TNF-alpha Protein, His Tag (Cat. No. TNA-H5228) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TNFR2 Protein, Fc,Avitag (Cat. No. TN2-H82F3) with a linear range of 0.01-0.313 μg/mL (QC tested).

TN2-M82E3-MALS-HPLC
TNFR2 MALS images

The purity of Biotinylated Mouse TNFR2 Protein, His,Avitag (Cat. No. TN2-M82E3) is more than 90% and the molecular weight of this protein is around 40-55 kDa verified by SEC-MALS.

Synonym Name

TNFRSF1B,CD120b,TBPII,TNF-R-II,TNF-R75,TNFBR,TNFR1B,TNFR2,TNFR80,p75,p75TNFR

Background

TNF RI is also known as the p60 or p55 TNFR) and TNF RII (the p75 or p80 TNFR) are two distinct type I transmembrane glycoproteins that bind TNF with highaffinity.Both RI and RII are prototypic members of the TNF receptor superfamily and have been designated TNFRSF1A and TNFRSF1B, respectively. Human TNF RII cDNA encodes a 461 amino acid (aa) residue precursor protein with a 22 aa putative signal peptide, a 235 aa extracellular domain, a 20 aa transmembrane domain and a 174 aa cytoplasmic domain. TNFRII is expressed in fetal brain. The protein is produced naturally as a soluble form (sTNFRII). The soluble receptor inhibits TNFα action by competing with cell surface receptors in binding TNFα, thereby blocking its biologic effects. TNFRII is strongly expressed at the cartilage–pannus junction, and plays a major role in a subset of families with multiple cases of  rheumatoid arthritis (RA). Further, high plasma levels of sTNFRII were significantly associated with increased incidence of coronary heart disease, independent of established cardiovascular risk factors, and seems to be useful for monitoring the inflammatory activity of sarcoidosis.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological) Approved Mainland China Psoriasis; Arthritis, Rheumatoid; Spondylitis, Ankylosing Hisun Biopharmaceutical Co Ltd 2015-04-09 Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis Details
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological) Approved Mainland China Psoriasis; Arthritis, Rheumatoid; Spondylitis, Ankylosing Hisun Biopharmaceutical Co Ltd 2015-04-09 Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LBL-019 LBL-019 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Neoplasms Details
BI-1910 BI-1910 Phase 2 Clinical Bioinvent International Ab Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
BITR-2101 BITR-2101; BIR-2101; BITT2101; BITT-2101 Phase 1 Clinical Infections; Neoplasms; Lymphoma, Non-Hodgkin Details
NBL-020 Phase 1 Clinical Shanghai Xinshi Biological Medicine Co Ltd Solid tumours; Neoplasms Details
SIM1811-03 SIM1811-03; SIM0235; SIM-235 Phase 1 Clinical Jiangsu Simcere Pharmaceutical Co Ltd Solid tumours; Neoplasms; Lymphoma, T-Cell, Cutaneous Details
HFB-2003(HiFiBiO Therapeutics) HFB-200301; HFB-2003 Phase 1 Clinical HiFiBiO Therapeutics Skin Melanoma; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Mesothelioma; Sarcoma; Testicular Neoplasms; Germinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis Details
LBL-019 LBL-019 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Neoplasms Details
BI-1910 BI-1910 Phase 2 Clinical Bioinvent International Ab Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
BITR-2101 BITR-2101; BIR-2101; BITT2101; BITT-2101 Phase 1 Clinical Infections; Neoplasms; Lymphoma, Non-Hodgkin Details
NBL-020 Phase 1 Clinical Shanghai Xinshi Biological Medicine Co Ltd Solid tumours; Neoplasms Details
SIM1811-03 SIM1811-03; SIM0235; SIM-235 Phase 1 Clinical Jiangsu Simcere Pharmaceutical Co Ltd Solid tumours; Neoplasms; Lymphoma, T-Cell, Cutaneous Details
HFB-2003(HiFiBiO Therapeutics) HFB-200301; HFB-2003 Phase 1 Clinical HiFiBiO Therapeutics Skin Melanoma; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Mesothelioma; Sarcoma; Testicular Neoplasms; Germinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop

Laisser un message